http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2000508672-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D261-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-423 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D261-20 |
| filingDate | 1997-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2000-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2000508672-A |
| titleOfInvention | Substituted benzylamines and their use for the treatment of depression |
| abstract | (57) The present invention relates to a compound of the formula (I) wherein R 1 and R 2 may be the same or different and each is C 6-12 aryl, C 2-14 heteroaryl, C 6 -12 aryl C 1-6 alkyl, C 2-14 heteroaryl C 1-6 alkyl (provided that the alkyl, aryl or heteroaryl moiety is C 1-6 alkoxy, C 1-6 alkyl, C 3-6 cycloalkyl , C 4-6 cycloalkenyl, C 6-12 aryl, C 2-14 heteroaryl, halogen, amino, hydroxy, halo C 1-6 alkyl, nitro, C 1-6 alkylthio, sulfonamide, C 1-6 alkyl Optionally substituted by one or more substituents selected from sulfonyl, hydroxy C 1-6 alkyl, C 1-6 alkoxycarbonyl, carboxyl, carboxy C 1-6 alkyl, carboxamide and C 1-6 alkyl carboxamide May be ), Hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, C 4-6 cycloalkenyl, C 2-6 alkenyl, C 2-6 alkynyl and C 1-6 alkoxy C 1-6 alkyl (however, alkyl , cycloalkyl, cycloalkenyl, alkenyl, alkynyl or alkoxyalkyl section, amino, halogen, hydroxy, C 1-6 alkylcarboxamide, carboxamide, carboxy, C 1-6 alkoxycarbonyl, C 1-6 alkyl carboxy and carboxy C 1 -6 optionally substituted with one or more substituents selected from alkyl) or one of R 1 and R 2 is as defined above and one is hydroxy in and, R 3 and R 4 may be the same or different, respectively, C 6-12 aryl, C 2-14 heteroaryl, C 6-12 aryl C 1-6 Al Le, C 2-14 heteroaryl C 1-6 alkyl (wherein the alkyl, aryl or heteroaryl moiety, C 1-6 alkoxy, C 1-6 alkyl, C 3-6 cycloalkyl, C 4-6 cycloalkenyl , C 6-12 aryl, C 2-14 heteroaryl, halogen, amino, hydroxy, halo C 1-6 alkyl, nitro, C 1-6 alkylthio, sulfonamide, C 1-6 alkylsulfonyl, hydroxy C 1-6 Alkyl, C 1-6 alkoxycarbonyl, carboxyl, carboxy C 1-6 alkyl, C 1-6 alkylcarboxamide and optionally substituted by one or more substituents selected from carboxamide), hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl C 1-6 alkyl, C 4-6 cycloalkenyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy 1-6 alkyl, halo C 1-6 alkyl, halo C 2-6 alkenyl, halo C 2-6 alkynyl, cyano, carboxyl, C 1-6 alkyl carboxy and carboxy C 1-6 alkyl (wherein the alkyl, cycloalkyl The cycloalkenyl, alkenyl, alkynyl or alkoxyalkyl moiety is selected from amino, hydroxy, C 1-6 alkylcarboxamide, carboxamide, carboxy, C 1-6 alkoxycarbonyl, C 1-6 alkylcarboxy and carboxy C 1-6 alkyl. Or one or more of R 3 or R 4 may be optionally substituted with one or more substituents described above, or one of R 1 or R 2 and to which it is attached together with the N atom, form a heterocyclic ring of 5- or 6-membered, R 5 is halogen, hydrogen, or C 1-6 alkyl and C 1-6 alkoxy It represents one or more ring substituents selected, and R 6 has the formula (A) (wherein the dotted line represents a bond optionally present, Y is oxygen or -NR 8 (R 8 is hydrogen Or C 1-6 alkyl) and R 7 is one or more substituents selected from hydrogen, halogen, haloC 1-6 alkyl, C 1-6 alkyl and C 1-6 alkoxy. Which represents a single ring substituent of the formula) or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to a method for its preparation, to pharmaceutical compositions containing it and to its use in medical therapy, in particular in the treatment of depression. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9035065-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2003510242-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012513993-A |
| priorityDate | 1996-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 401.